

# Assessment of association between Duffy blood group phenotypes and susceptibility to develop preeclampsia and its severity

ALIREZA REZVANI<sup>1</sup>, MOHAMMAD ALI TORABI<sup>2</sup>, EHSAN TAHERIFARD<sup>3</sup>, NASRIN ASADI<sup>4</sup>, ALIREZA AHMADKHANI<sup>5</sup>, ERFAN TAHERIFARD<sup>6</sup>

<sup>1</sup>Assistant Professor Of Hematology And Oncology, Shiraz Hematology Research Center, Shiraz, Fars, Iran

<sup>2</sup>Internist graduate of Shiraz University Of Medical Sciences, Shiraz, Fars, Iran

<sup>3,5,6</sup>Medical student at Shiraz University of Medical Sciences, Shiraz, Fars, Iran

<sup>4</sup>Assistant Professor of Perinatology, Maternal-fetal medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

Correspondence to : Erfan Taherifard, Email erfantaherifard@gmail.com, Telephone number: +989172810165

Address: Unit 2, No 26, Alley 19, Farhangshahr St, Shiraz, Fars, Iran

## ABSTRACT

**Aim:** To investigate the relationship between Duffy blood group and prevalence and severity of preeclampsia in pregnant women referred to Shiraz University of Medical Science affiliated hospitals.

**Methods:** This cross-sectional was conducted in the Hafez and Zeinabiyyeh hospitals. The study population consists of 53 preeclamptic women and 53 age-matched pregnant women without preeclampsia. Diagnosis of preeclampsia was conducted based on the American College of Obstetricians and Gynecologists (ACOG) criteria and preeclamptic women were divided to 2 subsets of preeclampsia with mild features and preeclampsia with severe ones.

**Results:** The results of current study showed no significant differences in frequency of different phenotypes of this blood group between the normotensive and preeclamptic patients ( $p$ -value= 0.094). Similarly, there was not any significant differences in prevalence of each type of Duffy phenotypes in two subsets of the preeclampsia ( $p$ -value= 0.831).

**Conclusion:** Day by day, the underlying pathologic pathways of formerly idiopathic diseases are being discovered. Genetic codes have been shown to highly affect these pathways, triggering a cascade that ends with the disease entity. However, our article does not support a significant association between different positive phenotypes of DARC and susceptibility to preeclampsia, these studies should be encouraged in order to delineate the underlying biologic pathways and their disruption in pathologic conditions.

**Keywords:** Duffy Blood-Group System; DARC protein, human [Supplementary Concept]; Pre-Eclampsia

## INTRODUCTION

Preeclampsia is a multisystem disorder characterized by endothelial cell dysfunction and neutrophil activation<sup>1</sup>. It's defined as a hypertension developed at second half of pregnancy with either significant end-organ damage and/or proteinuria<sup>2</sup>. It has been reported that 2-8% of all pregnant women worldwide experience preeclampsia and its deleterious effects; Also, near to 16% of maternal deaths are caused by hypertensive disorders<sup>3</sup>. Furthermore, preeclampsia can lead to lots of short-term and long-term complications in both mother and fetus. Acute maternal complications include: eclampsia, stroke, abruptio placentae, disseminated intravascular coagulation, HELLP syndrome, liver hemorrhage/rupture, pulmonary aspiration/edema, adult respiratory distress syndrome, acute renal failure, cerebral hemorrhage and even death<sup>4,5,6</sup>. Long-term maternal complications include: chronic hypertension, diabetes mellitus, chronic renal failure, coronary artery disease and neurologic deficit<sup>7</sup>. The fetal burden of the disease mainly results from placental hypoperfusion. Even though termination of pregnancy may reduce maternal and fetal mortality and morbidity, it would get rise to birth of a premature neonate with neurological sequelae of preterm delivery<sup>8</sup>.

It is thought that both genetic factors and environmental factors play an important role in disease susceptibility<sup>9,10,11</sup>. Besides, several maternal, fetal and fetomaternal mechanisms have been suggested for pathophysiology of preeclampsia; in these all mechanisms,

abnormal development of placental vasculature early in pregnancy is involved<sup>12,13,14,15</sup>. However, there are still some gaps about the molecular pathway that are not fully understood<sup>16,17</sup>; in other words, the main trigger for abnormal development of placental tissue and the subsequent cascade of events remains unknown.

Duffy Antigen Receptor for Chemokines (DARC) which is known as Fy glycoprotein (FY), is supposed to be one of the effective factors in incidence of preeclampsia<sup>18</sup>. This glycosylated membrane protein is ubiquitously found on surface of the red blood cells and endothelial cells of postcapillary venules<sup>19,20</sup>. Duffy antigen is a potent nonspecific receptors of a variety of different chemokines<sup>21,22</sup>; among these chemokines, Interleukin-8 (IL-8) is seen to be the most intensively ligand of the DARC<sup>23</sup> and it is one of the most important neutrophil chemoattractant and activators<sup>24</sup>. On the other hand, this interleukin, is reported to be at high levels during pregnancy and even increases significantly in a preeclamptic women compared to a normotensive pregnant<sup>25,26,27</sup>.

This probable relationship between preeclamptic event and Duffy antigen system has not been completely evaluated; therefore, this study conducted to investigate the relationship between Duffy blood group and prevalence and severity of preeclampsia in pregnant women referred to Shiraz University of Medical Science affiliated hospitals.

## METHODS

This cross-sectional study was conducted in the teaching hospitals affiliated to Shiraz University of Medical Sciences, Hafez and Zeinabiyyeh hospitals. The data of this study was gathered between 21<sup>th</sup> of March, 2016 and 20<sup>th</sup> March, 2018. The target patient group of the study were those patients referred to these two hospitals and diagnosed by preeclampsia in that period. The control group were chosen from age-matched pregnant women without preeclampsia referred there.

Diagnosis of preeclampsia was conducted based on the American College of Obstetricians and Gynecologists (ACOG) criteria<sup>28</sup>: these patients were labeled as preeclampsia if they have new-onset of hypertension after the week 20<sup>th</sup> of gestation (Systolic Blood Pressure (SBP)  $\geq 140$  mmHg or Diastolic Blood Pressure (DBP)  $\geq 90$  mmHg on two occasions at least four hours apart), accompanied with proteinuria (Protein  $\geq 1+$  in on dipstick or a protein:creatinine ratio of more than 0.3 in a spot urine sample) or new-onset of any of the followings: platelet count  $< 100,000/\mu\text{l}$ , serum creatinine  $> 1.1$  mg/dL in the absence of other renal disease, liver transaminases at least twice the upper limit of the normal concentrations, pulmonary edema, cerebral or visual symptoms such as blurred vision, headache and etc. However, in absent of these signs and symptoms or proteinuria, if the patient had SBP  $\geq 160$  mmHg or a DBP  $\geq 110$  mmHg, she was included in the patient group of the study.

In this study, preeclamptic women were divided to 2 subsets of preeclampsia with mild features and preeclampsia with severe ones; women with SBP  $\geq 160$  mmHg or a DBP  $\geq 110$  mmHg and proteinuria were included in the severe group. Furthermore, those women with SBP  $\geq 140$  mmHg or DBP  $\geq 90$  mmHg (with or without proteinuria) were considered as preeclamptic patient with severe features only if they had at least one of the signs and symptoms of significant end-organ dysfunction: new-onset cerebral or visual disturbance, platelet count of less than  $100,000/\mu\text{l}$ , unstopable severe and persistent right

upper quadrant or epigastric pain with unknown cause, serum transaminase concentration  $\geq 2$  times upper limit of normal, pulmonary edema and progressive renal insufficiency (serum creatinine  $> 1.1$  mg/dL). Other women were categorized as preeclamptic patients with mild features.

2 milliliters blood sample was obtained from both preeclamptic and normotensive women in EDTA tubes and sent to the laboratory for determination Duffy blood group antigens. The method used for antigens identification was based on AGH Maestria IGG (DIAGAST, France).

Afterwards, collected data were analyzed using IBM Statistical Package for the Social Sciences (SPSS) 24 software. Chi-squared test was used to compare the phenotype frequencies of Duffy blood antigens between two groups of preeclamptic patients and the controls. P-values less than 0.05 were considered statistically significant.

## RESULTS

A total of 53 patients were admitted to obstetric ward of Hafez and Zeinabiyyeh hospitals as preeclamptic patient between 21<sup>th</sup> of March, 2016 and 20<sup>th</sup> March, 2018. The same number of participants were chosen from age-matched hospitalized patients without preeclampsia and they were included in the study as the controls. Of those preeclamptic patients, 36 (67.9%) patients were diagnosed as preeclampsia with mild features and the others had preeclampsia with severe ones (Table 1). Ages of participants ranged from 22 to 41 with the average of  $30.01 \pm 4.6$  years ( $p=0.56$ ). In overall in our study, the most common phenotype was FYa with 38.6%, followed by FY(a+/b+) with 34.9% and FYb with 26.4% (Table 1). Statistical analyses showed no significant differences in frequency of different phenotypes of this blood group between the normotensive and preeclamptic patients ( $p$ -value = 0.094). Similarly, there was not any significant differences in prevalence of each type of Duffy phenotypes in two subsets of the preeclampsia ( $p$ -value = 0.831).

Table 1. The prevalence of different phenotypes of Duffy blood group among the patient and control group.

| Status of the study participants | Phenotype |          |                             | Total |
|----------------------------------|-----------|----------|-----------------------------|-------|
|                                  | FYa       | FYb      | Double positive (FY(a+/b+)) |       |
| Normotensive                     | 23(43.3)  | 12(22.6) | 18(33.9)                    | 53    |
| <b>Preeclamptic</b>              |           |          |                             |       |
| Mild                             | 13(36.1)  | 10(18.8) | 13(36.1)                    | 36    |
| Severe                           | 5(29.4)   | 6(35.2)  | 6(29.4)                     | 17    |
| Total                            | 41(38.6)  | 28(26.4) | 37(34.9)                    | 106   |

## DISCUSSION

Duffy antigen, also known as Fy glycoprotein, is a membrane receptor playing as a mediator in chemokine signal transduction pathways<sup>29</sup>. Throughout these several recent decades, scholars have stared investigations about the clinical significance of blood groups other than ABO and Rh blood group systems; Duffy antigen system as well as other blood group systems has been worked up to clarify its participation in pathogenesis of several both inflammatory and non-inflammatory diseases.

Studies has documented the Duffy antigen to be involved in pathogenesis of a variety of diseases such as suppurative pneumonia, asthma, rheumatoid arthritis, CNS autoimmune diseases, etc<sup>30-33</sup>. In a study by Lee JS et al., DARC expression was showed to be increased in the lung pre- and postcapillary parenchymal vessels and alveolar septa in the course of a suppurative pneumonia<sup>30</sup>. In 2008, Candelaria Vergara et al. found the rs2814778 polymorphism in DARC gene to be associated with higher levels of IgE among certain populations of the African descent, predisposing them to higher prevalence of asthma and its severity<sup>31</sup>. In a study conducted by Emily Smith and her colleagues, it was illustrated that Duffy antigen is

upregulated in early rheumatoid arthritis and has a determining role in recruitment of neutrophils to the synovium<sup>32</sup>. In another study by Carsten Minten et al., they demonstrated that Duffy receptors are upregulated in autoimmune encephalomyelitis, conveying proinflammatory cytokines from luminal to abluminal surfaces of the blood-brain barrier<sup>33</sup>. Furthermore, DARC-positive small vessels, especially alveolar wall capillaries, were associated with inflammatory sites that were marked by interstitial CCR5-positive T-cell and CXCR1-positive leukocyte infiltrates. The study, also, revealed increased expression of Duffy receptors during acute phase of lung rejection<sup>34</sup>.

Interestingly, even, the different positive phenotypes of DARC (FY (a+/b-), FYb (a-/b+), FY (a+/b+)) has been corroborated to be determinant in susceptibility of various diseases and, surprisingly, their severity. Based on a study conducted in 2009, Nil Guler et al. concluded that higher ratios of phenotype FY (a+/b+) is seen in patients with multiple myeloma than healthy ones<sup>35</sup>. In another study by Mun Yik Fong et al., they figured out that Plasmodium knowlesi has higher binding affinity for erythrocytes with FY (a+/b+) antigens than those with only FYa antigens<sup>36</sup>. In 2018, it was further demonstrated that patients with FY (a-/b+) phenotype are more susceptible to develop clinical malaria; however, those with FY (a+/b-) phenotype are more likely to be asymptomatic<sup>37</sup>. Despite these, our study provides no significant association between the three different Duffy positive phenotypes and increased risk of developing preeclampsia among the study population. This finding does not mean that no association exists between DARC phenotypes and susceptibility to preeclampsia; as those with Duffy null phenotypes were not included in our study due to the low prevalence of FY(a-/b-) phenotype among Caucasians<sup>38</sup>. Therefore, comparison between the prevalence of preeclamptic toxemia among them and those with Duffy positive phenotypes has not been investigated in the current research. Further studies are demanded to be designed in this area to investigate possible effect of DARC presence or its absence in preeclampsia pathogenesis. Such analyses should be encouraged in order to delineate the underlying biologic pathways and their disruption in pathologic conditions.

## CONCLUSION

Day by day, the underlying pathologic pathways of formerly idiopathic diseases are being discovered. Genetic codes have been shown to highly affect these pathways, triggering a cascade that ends with the disease entity. However, our article does not support a significant association between different positive phenotypes of DARC and susceptibility to preeclampsia, these studies should be encouraged in order to delineate the underlying biologic pathways and their disruption in pathologic conditions.

## REFERENCES

1. Regal JF, Burwick RM, Fleming SD. The Complement System and Preeclampsia. *Curr Hypertens Rep*. 2017;19(11):87-87. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/29046976>  
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5849056/>. ^10.1007/s11906-017-0784-4

2. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines. *Clinical journal of the American Society of Nephrology : CJASN*. 2016;11(6):1102-13. ^10.2215/cjn.12081115.PMC4891761.
3. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. *Obstetrics and gynecology*. 2019;133(1):e1-e25. ^10.1097/aog.0000000000003018
4. Grotegut CA. Prevention of preeclampsia. *The Journal of clinical investigation*. 2016;126(12):4396-98. ^10.1172/jci91300.PMC5127661.
5. Karumanchi SA, Granger JP. Preeclampsia and Pregnancy-Related Hypertensive Disorders. *Hypertension (Dallas, Tex : 1979)*. 2016;67(2):238-42. ^10.1161/hypertensionaha.115.05024.PMC4755281.
6. Weekes LR. Renal shutdown as a complication of severe preeclampsia with premature separation of the placenta. *Journal of the National Medical Association*. 1980;72(5):481-5. PMC2552436.
7. Ghulmiyyah L, Sibai B. Maternal mortality from preeclampsia/eclampsia. *Seminars in perinatology*. 2012;36(1):56-9. ^10.1053/j.semperi.2011.09.011
8. van Esch JJA, van Heijst AF, de Haan AFJ, van der Heijden OWH. Early-onset preeclampsia is associated with perinatal mortality and severe neonatal morbidity. *The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet*. 2017;30(23):2789-94. ^10.1080/14767058.2016.1263295
9. Esplin MS, Fausett MB, Fraser A, Kerber R, Mineau G, Carrillo J, et al. Paternal and maternal components of the predisposition to preeclampsia. *The New England journal of medicine*. 2001;344(12):867-72. ^10.1056/nejm200103223441201
10. Arngimsson R, Siguroardottir S, Frigge ML, Bjarnadottir RI, Jonsson T, Stefansson H, et al. A genome-wide scan reveals a maternal susceptibility locus for pre-eclampsia on chromosome 2p13. *Human molecular genetics*. 1999;8(9):1799-805. ^10.1093/hmg/8.9.1799
11. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. *BMJ (Clinical research ed)*. 2005;330(7491):565. ^10.1136/bmj.38380.674340.E0.PMC554027.
12. Kaufmann P, Black S, Huppertz B. Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia. *Biology of reproduction*. 2003;69(1):1-7. ^10.1095/biolreprod.102.014977
13. Reister F, Frank HG, Kingdom JC, Heyl W, Kaufmann P, Rath W, et al. Macrophage-induced apoptosis limits endovascular trophoblast invasion in the uterine wall of preeclamptic women. *Laboratory investigation; a journal of technical methods and pathology*. 2001;81(8):1143-52
14. Caniggia I, Winter J, Lye SJ, Post M. Oxygen and placental development during the first trimester: implications for the pathophysiology of pre-eclampsia. *Placenta*. 2000;21 Suppl A:S25-30
15. Goulopoulou S, Davidge ST. Molecular mechanisms of maternal vascular dysfunction in preeclampsia. *Trends in molecular medicine*. 2015;21(2):88-97. ^10.1016/j.molmed.2014.11.009
16. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. *Lancet (London, England)*. 1993;341(8858):1447-51. ^10.1016/0140-6736(93)90889-o
17. Kashiwagi M, Zimmermann R, Beinder E. Pathophysiology of pre-eclampsia: update on the role of nitric oxide. *Curr Hypertens Rep*. 2003;5(6):493-7
18. Velzing-Aarts FV, van der Dijns FP, Muskiet FA, Duits AJ. The association of pre-eclampsia with the Duffy negative phenotype in women of West African descent. *BJOG : an*

- international journal of obstetrics and gynaecology. 2002;109(4):453-5
19. Peiper SC, Wang ZX, Neote K, Martin AW, Showell HJ, Conklyn MJ, et al. The Duffy antigen/receptor for chemokines (DARC) is expressed in endothelial cells of Duffy negative individuals who lack the erythrocyte receptor. *The Journal of experimental medicine*. 1995;181(4):1311-7. [10.1084/jem.181.4.1311](https://doi.org/10.1084/jem.181.4.1311).PMC2191961.
  20. Tournamille C, Blancher A, Le Van Kim C, Gane P, Apoil PA, Nakamoto W, et al. Sequence, evolution and ligand binding properties of mammalian Duffy antigen/receptor for chemokines. *Immunogenetics*. 2004;55(10):682-94. [10.1007/s00251-003-0633-2](https://doi.org/10.1007/s00251-003-0633-2)
  21. Gardner L, Patterson AM, Ashton BA, Stone MA, Middleton J. The human Duffy antigen binds selected inflammatory but not homeostatic chemokines. *Biochemical and biophysical research communications*. 2004;321(2):306-12. [10.1016/j.bbrc.2004.06.146](https://doi.org/10.1016/j.bbrc.2004.06.146)
  22. Langhi DM, Jr., Bordin JO. Duffy blood group and malaria. *Hematology (Amsterdam, Netherlands)*. 2006;11(5):389-98. [10.1080/10245330500469841](https://doi.org/10.1080/10245330500469841)
  23. Moreno Velasquez I, Kumar J, Bjorkbacka H, Nilsson J, Silveira A, Leander K, et al. Duffy antigen receptor genetic variant and the association with Interleukin 8 levels. *Cytokine*. 2015;72(2):178-84. [10.1016/j.cyto.2014.12.019](https://doi.org/10.1016/j.cyto.2014.12.019)
  24. Bickel M. The role of interleukin-8 in inflammation and mechanisms of regulation. *Journal of periodontology*. 1993;64(5 Suppl):456-60
  25. Velzing-Aarts FV, Muskiet FA, van der Dijs FP, Duits AJ. High serum interleukin-8 levels in afro-caribbean women with preeclampsia. Relations with tumor necrosis factor-alpha, duffy negative phenotype and von Willebrand factor. *American journal of reproductive immunology (New York, NY : 1989)*. 2002;48(5):319-22
  26. Kocyigit Y, Atamer Y, Atamer A, Tuzcu A, Akkus Z. Changes in serum levels of leptin, cytokines and lipoprotein in preeclamptic and normotensive pregnant women. *Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology*. 2004;19(5):267-73
  27. Yang W, Wang A, Zhao C, Li Q, Pan Z, Han X, et al. miR-125b Enhances IL-8 Production in Early-Onset Severe Preeclampsia by Targeting Sphingosine-1-Phosphate Lyase 1. *PloS one*. 2016;11(12):e0166940. [10.1371/journal.pone.0166940](https://doi.org/10.1371/journal.pone.0166940).PMC 5147846.
  28. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' Task Force on Hypertension in Pregnancy. *Obstetrics and gynecology*. 2013;122(5):1122-31. [10.1097/01.AOG.0000437382.03963.88](https://doi.org/10.1097/01.AOG.0000437382.03963.88)
  29. Ntumngia FB, Thomson-Luque R, Pires CV, Adams JH. The role of the human Duffy antigen receptor for chemokines in malaria susceptibility: current opinions and future treatment prospects. *J Receptor Ligand Channel Res*. 2016;9:1-11. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/28943755> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608092/>. [10.2147/JRLCR.S99725](https://doi.org/10.2147/JRLCR.S99725)
  30. Lee JS, Frevert CW, Thorning DR, Segerer S, Alpers CE, Cartron JP, et al. Enhanced expression of Duffy antigen in the lungs during suppurative pneumonia. *The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society*. 2003;51(2):159-66. [10.1177/002215540305100204](https://doi.org/10.1177/002215540305100204)
  31. Vergara C, Tsai YJ, Grant AV, Rafaels N, Gao L, Hand T, et al. Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. *American journal of respiratory and critical care medicine*. 2008;178(10):1017-22. [10.1164/rccm.200801-182OC](https://doi.org/10.1164/rccm.200801-182OC).PMC2582596.
  32. Smith E, McGettrick HM, Stone MA, Shaw JS, Middleton J, Nash GB, et al. Duffy antigen receptor for chemokines and CXCL5 are essential for the recruitment of neutrophils in a multicellular model of rheumatoid arthritis synovium. *Arthritis and rheumatism*. 2008;58(7):1968-73. [10.1002/art.23545](https://doi.org/10.1002/art.23545).PMC2821686.
  33. Minten C, Alt C, Gentner M, Frei E, Deutsch U, Lyck R, et al. DARC shuttles inflammatory chemokines across the blood-brain barrier during autoimmune central nervous system inflammation. *Brain : a journal of neurology*. 2014;137(Pt 5):1454-69. [10.1093/brain/awu045](https://doi.org/10.1093/brain/awu045).PMC3999718.
  34. Geleff S, Draganovici D, Jaksch P, Segerer S. The role of chemokine receptors in acute lung allograft rejection. *The European respiratory journal*. 2010;35(1):167-75. [10.1183/09031936.00042309](https://doi.org/10.1183/09031936.00042309)
  35. Guler N, Turgut M, Ozatli D, Turgut Y, Gokce AK, Koc S, et al. High ratio of Duffy (a+b+) phenotype in patients with multiple myeloma compared to healthy controls. *Hematological oncology*. 2009;27(1):50-1. [10.1002/hon.887](https://doi.org/10.1002/hon.887)
  36. Fong MY, Cheong FW, Lau YL. Erythrocyte-binding assays reveal higher binding of Plasmodium knowlesi Duffy binding protein to human Fy(a+b+) erythrocytes than to Fy(a+b-) erythrocytes. *Parasites & vectors*. 2018;11(1):527. [10.1186/s13071-018-3118-8](https://doi.org/10.1186/s13071-018-3118-8).PMC6158824.
  37. Kano FS, de Souza AM, de Menezes Torres L, Costa MA, Souza-Silva FA, Sanchez BAM, et al. Susceptibility to Plasmodium vivax malaria associated with DARC (Duffy antigen) polymorphisms is influenced by the time of exposure to malaria. *Sci Rep*. 2018;8(1):13851-51. Available from: <https://www.ncbi.nlm.nih.gov/pubmed/30218021> <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6138695/>. [10.1038/s41598-018-32254-z](https://doi.org/10.1038/s41598-018-32254-z)
  38. Dean L. Blood groups and red cell antigens: National Center for Biotechnology Information; 2005.